Related scientific articles (all)

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Authors : Najem A, Krayem M, Sales F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem G
Year : 2017
Journal : Eur J Cancer
Volume : 83
Pages : 154-165

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Authors : Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S
Year : 2017
Journal : Lancet Oncol
Volume : 18(1)
Pages : 52-62

Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?

Authors : Kourie HR, Gharios J, Kattan J
Year : 2017
Journal : Future Oncol
Volume : 13(3)
Pages : 197-99

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Car

Authors : Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, OToole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB
Year : 2017
Journal : Adv Anat Pathol
Volume : 24
Pages : 311-335

Unusual presentation of nasopharyngeal carcinoma with rectal metastasis.

Authors : Vogel M, Kourie HR, Piccart-Gebhart M, Lalami Y
Year : 2017
Journal : World J Clin Cases
Volume : 5
Pages : 183-186

Adjuvant trastuzumab: a 10-year overview of its benefit.

Authors : Lambertini M, Pondé NF, Solinas C, de Azambuja E
Year : 2017
Journal : Expert Rev Anticancer Ther
Volume : 17
Pages : 61-74

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.

Authors : Holbrechts S, Gorham J, Sideris S, Meert AP, Durieux V, Berghmans T, Sculier JP
Year : 2017
Journal : Lung Cancer
Volume : 106
Pages : 93-101

ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2340-2366

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Authors : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Year : 2017
Journal : EMBO Mol Med
Volume : 9
Pages : 1052-1066

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

Authors : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Piccart-Gebhart M
Year : 2017
Journal : PLoS One
Volume : 12(3)
Pages : e0172351

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

Authors : Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, OToole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB
Year : 2017
Journal : Adv Anat Pathol
Volume : 24
Pages : 235-251

Tackling immunomonitoring in gastrointestinal cancer.

Authors : Anciaux M, Vandeputte C, Hendlisz A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29
Pages : 296-305

PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors.

Authors : Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J
Year : 2017
Journal : Cancer Res
Volume : 77(2)
Pages : 312-9

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Authors : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, DHondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Year : 2017
Journal : Clin Genitourin Cancer
Volume : 15(4)
Pages : 502-508

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Authors : Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : iv84-iv99

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors : Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M
Year : 2017
Journal : Lancet Oncol
Volume : 18(7)
Pages : 904-916

Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Authors : Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, Van Velthoven R
Year : 2017
Journal : BJU Int
Volume : 120(2)
Pages : 197-203

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Authors : Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF
Year : 2017
Journal : BMJ Open
Volume : 7(11)
Pages : e017075

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Authors : Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M
Year : 2017
Journal : Nat Rev Clin Oncol
Volume : 14(11)
Pages : 669-681

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Year : 2017
Journal : N Engl J Med
Volume : 377(2)
Pages : 122-131